BeOne Medicines (NASDAQ:ONC) SVP Sells 10,006 Shares

Key Points

• Chan Henry Lee, SVP of BeOne Medicines, sold 10,006 shares at an average price of $325.53, totaling approximately $3.26 million, with the transaction disclosed to the SEC.
• BeOne Medicines reported $1.32 billion in revenue for the last quarter, exceeding analyst expectations and posting $0.84 EPS, surpassing estimates of $0.48.
• Wall Street analysts have a consensus "Buy" rating for BeOne Medicines, with price targets from multiple firms ranging from $330 to $365.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 10,006 shares of the business's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $325.53, for a total transaction of $3,257,253.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, August 13th, Chan Henry Lee sold 11,013 shares of BeOne Medicines stock. The stock was sold at an average price of $300.45, for a total transaction of $3,308,855.85.
• On Wednesday, July 30th, Chan Henry Lee sold 920 shares of BeOne Medicines stock. The stock was sold at an average price of $304.60, for a total transaction of $280,232.00.
• On Monday, June 16th, Chan Henry Lee sold 422 shares of BeOne Medicines stock. The shares were sold at an average price of $266.50, for a total value of $112,463.00.

BeOne Medicines Stock Up 1.5%

Shares of NASDAQ ONC traded up $5.00 during midday trading on Wednesday, hitting $332.20. 157,818 shares of the stock traded hands, compared to its average volume of 337,094. The company has a market cap of $36.41 billion, a PE ratio of -192.02 and a beta of 0.21. The business has a 50 day moving average price of $305.23 and a two-hundred day moving average price of $267.01. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.72 and a current ratio of 1.95. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $170.99 and a one year high of $351.27.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The firm had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. On average, equities analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Institutional Trading of BeOne Medicines

Several hedge funds and other institutional investors have recently modified their holdings of ONC. Primecap Management Co. CA purchased a new position in BeOne Medicines in the 2nd quarter valued at approximately $1,231,720,000. Temasek Holdings Private Ltd purchased a new stake in shares of BeOne Medicines during the second quarter worth $244,603,000. Marshall Wace LLP bought a new position in shares of BeOne Medicines in the second quarter worth $113,190,000. Baird Financial Group Inc. purchased a new position in shares of BeOne Medicines in the second quarter valued at $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of BeOne Medicines in the second quarter valued at $73,347,000. Institutional investors own 48.55% of the company's stock.

Wall Street Analyst Weigh In

ONC has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their target price on BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. Guggenheim upped their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Morgan Stanley increased their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, June 27th. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen cut shares of BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, BeOne Medicines presently has a consensus rating of "Buy" and a consensus price target of $330.89.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.